VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Sees Significant Decrease in Short Interest

VistaGen Therapeutics, Inc. (NASDAQ:VTGN) saw a significant decline in short interest during the month of January. As of January 15th, there was short interest totaling 2,441,031 shares, a decline of 27.9% from the December 31st total of 3,385,220 shares. Based on an average trading volume of 1,563,145 shares, the days-to-cover ratio is presently 1.6 days. Currently, 6.4% of the shares of the stock are sold short. Currently, 6.4% of the shares of the stock are sold short. Based on an average trading volume of 1,563,145 shares, the days-to-cover ratio is presently 1.6 days.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of VTGN. Cubist Systematic Strategies LLC acquired a new position in VistaGen Therapeutics during the 1st quarter valued at approximately $25,000. Schonfeld Strategic Advisors LLC bought a new stake in VistaGen Therapeutics in the third quarter valued at $39,000. Bank of America Corp DE boosted its holdings in shares of VistaGen Therapeutics by 1,068.0% during the fourth quarter. Bank of America Corp DE now owns 21,141 shares of the company’s stock valued at $62,000 after acquiring an additional 19,331 shares during the period. Marshall Wace LLP bought a new position in shares of VistaGen Therapeutics during the second quarter worth about $69,000. Finally, Millennium Management LLC acquired a new stake in shares of VistaGen Therapeutics in the 3rd quarter worth about $73,000. 78.39% of the stock is currently owned by institutional investors.

Key VistaGen Therapeutics News

Here are the key news stories impacting VistaGen Therapeutics this week:

• Neutral Sentiment: Lead-plaintiff deadline and class period: Multiple notices remind investors that the lead-plaintiff deadline is March 16, 2026 and define the alleged class period as April 1, 2024–December 16, 2025; this is procedural but sets the timetable for litigation consolidation and potential claims. ROSEN reminder
• Negative Sentiment: Multiple firms have filed or are soliciting class actions/investigations (Rosen, Pomerantz, Bragar Eagel & Squire, Levi & Korsinsky, Bronstein Gewirtz & Grossman, Faruqi & Faruqi, Schall, DJS, Gross Law and others). That coordinated legal activity suggests elevated litigation exposure; outcomes could include defense costs, settlements or judgment risk that would likely weigh on VTGN’s share price and financing flexibility. Representative filing/notice: Bragar notice

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of VistaGen Therapeutics in a research note on Wednesday, January 21st. Maxim Group reaffirmed a “hold” rating on shares of VistaGen Therapeutics in a research note on Wednesday, December 17th. Jefferies Financial Group restated a “hold” rating and set a $0.90 price objective (down previously from $15.00) on shares of VistaGen Therapeutics in a report on Wednesday, December 17th. Wall Street Zen downgraded VistaGen Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, December 20th. Finally, Stifel Nicolaus downgraded VistaGen Therapeutics from a “buy” rating to a “hold” rating and set a $1.00 target price on the stock. in a research report on Wednesday, December 17th. Four research analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Reduce” and an average price target of $0.95.

VistaGen Therapeutics Trading Up 3.1%

NASDAQ:VTGN traded up $0.02 during trading hours on Friday, hitting $0.56. The stock had a trading volume of 658,546 shares, compared to its average volume of 1,281,000. The business has a 50 day simple moving average of $1.93 and a two-hundred day simple moving average of $2.96. VistaGen Therapeutics has a 1-year low of $0.54 and a 1-year high of $5.14. The company has a market cap of $22.04 million, a PE ratio of -0.29 and a beta of 0.31.

VistaGen Therapeutics (NASDAQ:VTGN) last announced its earnings results on Thursday, November 13th. The company reported ($0.54) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.03). The firm had revenue of $0.26 million during the quarter, compared to analyst estimates of $0.16 million. Research analysts expect that VistaGen Therapeutics will post -1.77 EPS for the current fiscal year.

VistaGen Therapeutics Company Profile

VistaGen Therapeutics, Inc (NASDAQ:VTGN) is a clinical-stage biopharmaceutical company dedicated to the discovery and development of next-generation medicines for central nervous system disorders. Incorporated in Delaware in 1998 and headquartered in South San Francisco, California, VistaGen applies advanced human pluripotent stem cell technologies to accelerate drug candidate validation and optimization. The company’s core focus is on addressing unmet medical needs in major depressive disorder, neuropathic pain and dermatological conditions.

The company’s lead candidate, AV-101, is an oral prodrug designed to modulate glutamatergic neurotransmission via the N-methyl-D-aspartate (NMDA) receptor pathway, with clinical programs targeting major depressive disorder and neuropathic pain.